Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVT-201
- Development stage
- Preclinical
- Lead developer
- Microviable Therapeutics
- Modality
- Salmonella Species → Oncolytic Bacteria → Oncolytic Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Clostridium Species → Oncolytic Bacteria → Oncolytic Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
MVT-201 is a preclinical, orally administered, live biotherapeutic product developed by Microviable Therapeutics. [3] It consists of a complete, purified gut microbiota ecosystem derived from donors, manufactured using a proprietary process (HPM®) that preserves high bacterial diversity and richness while removing non-microbial fecal components. [2, 3] It is being developed as a bacterial immunotherapy to modulate the gut microbiome for multiple indications, including infectious diseases caused by multidrug-resistant organisms (such as recurrent urinary tract infections), colorectal cancer, and as an adjuvant to enhance the efficacy of immunotherapy in solid tumors. [2]
Beyond the preview
Go deeper on MVT-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVT-201.